ClinicalTrials.gg
CompletedNCT02425111Updated Sep 14, 2018Results posted

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

A Phase 3 interventional study of Vedolizumab in Crohn's Disease, sponsored by Takeda. Completed at 81 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-09-14.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Enrollment
20th of 39
101 · median 101
Started
2015
with 1 other
Phase 3
16 of 39
6 open now
Registered
7th of 39
by date
Lead sponsor
25 of 39
Takeda

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 20th largest by enrollment, is one of 2 that started in 2015, is one of 16 in phase 3, and was the 7th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.

Read the detailed description

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have Crohn's disease. This study will look at mucosal healing in people who take vedolizumab.

The study will enroll approximately 100 patients and will be conducted in 2 Parts. Part A will consist of a 26-week treatment period and all participants will receive vedolizumab 300 mg intravenously (IV) on Day 1 and at Weeks 2, 6, 14 and 22. Part B will consist of a 26-week extension treatment period and all participants will receive vedolizumab 300 mg IV at Weeks 30, 38, and 46.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 70 weeks for Parts A, B and 18-Week Follow-up combined. Participants will make multiple visits to the clinic. All participants included in the study will also have a 6 month safety follow-up telephone call following his/her last dose of study drug.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. Signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has a diagnosis of moderately to severely active Crohn's disease (CD) at least 3 months prior to enrollment, with a Crohn's Disease Activity Index (CDAI) score of 220-450 during the Screening Period, a simple endoscopic score for Crohn's Disease (SES-CD) score of ≥7 and presence of at least one mucosal ulceration documented by recorded ileocolonoscopy at Screening assessed by the central reader.
  4. Has CD with involvement of the ileum and/or colon that can be assessed by ileocolonoscopy.
  5. Is male or female and aged 18 to 80 years, inclusive.
  6. A male participant who is nonsterilized and sexually active with a female partner of agrees to use adequate from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.
  7. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.
  8. Has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:

    • Immunomodulators:

      i. Has signs and symptoms of persistently active disease despite a history of at least one 12-week regimen of oral azathioprine (≥1.5 mg/kg) or 6-mercaptopurine (≥0.75 mg/kg), OR ii. Has a history of intolerance (including but not limited to nausea/vomiting, abdominal pain, pancreatitis, liver function test abnormalities, lymphopenia, thiopurine S-methyltransferase non wild type [where wild type is defined as thiopurine S-methyltransferase (TPMT)*1/*1], infection) to at least 1 immunomodulator.

    • Tumor necrosis factor- alpha (TNF-α) antagonists:

      i. Has signs and symptoms of persistently active disease despite a history of at least 1 induction with:

      1. Infliximab: 4-week regimen of 5 mg/kg, 2 doses at 2 weeks apart, OR
      2. Adalimumab: 2-week regimen of 160 mg on Day 1 and 80 mg on Day 15, OR
      3. Certolizumab: 4-week regimen of 400 mg initially at Weeks 0, 2, 4 OR ii. Has recurrence of symptoms during maintenance dosing following prior clinical benefit (discontinuation despite clinical benefit does not qualify), OR iii. Has a history of intolerance of infliximab, adalimumab, or certolizumab, including but not limited to, infusion-related reaction, demyelination, congestive heart failure, or infection.
    • i. Signs and symptoms of persistently active disease despite a history of at least one 4-week induction regimen that included a dose equivalent to prednisone 30 mg daily orally for 2 weeks or intravenous(ly) (IV) for 1 week, OR ii. Signs and symptoms of persistently active disease despite treatment with budesonide 9 mg daily or 6 mg daily for maintenance, OR iii. At least one failed attempt to taper corticosteroids to below a dose equivalent to prednisone 10 mg daily orally, OR iv. History of intolerance to corticosteroids (including, but not limited to, Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, and infection).
  9. May be receiving a stable therapeutic dose of conventional therapies for CD (excluding other biologic agents 60 days before enrollment).
  10. Has a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factors must be up-to-date on colorectal cancer surveillance (may be performed during Screening).

Exclusion criteria

Exclusion Criteria:

  1. Has received a diagnosis of ulcerative colitis or indeterminate colitis.
  2. Has clinical evidence of abdominal abscess.
  3. Has a history of >3 small bowel resections or diagnosis of short bowel syndrome.
  4. Has extensive colonic resection, ie, subtotal or total colectomy with \<15 cm colon remaining.
  5. Has ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
  6. Has a history or evidence of adenomatous colonic polyps that have not been removed.
  7. Has a history or evidence of colonic mucosal dysplasia.
  8. Has intolerance or to undergo ileocolonoscopy.
  9. Has active or latent tuberculosis, regardless of treatment history, as evidenced by any of the following:

    a. History of tuberculosis (TB). b. A diagnostic TB test performed during screening that is positive, as defined by: i. A positive QuantiFERON® test or 2 successive indeterminate QuantiFERON tests OR ii. A tuberculin skin test reaction ≥10 mm (≥5 mm in participants receiving the equivalent of >15 mg/day prednisone).

  10. Has chronic (HBV) or (HCV) infection.
  11. Has any identified congenital or acquired immunodeficiency (eg, common variable immunodeficiency, [HIV] infection, organ transplantation).
  12. Has evidence of active C. difficile infection or is having treatment for C. difficile infection or other intestinal pathogens during Screening.
  13. Has evidence of an active infection during Screening.
  14. Currently requires or has a planned surgical intervention for CD during the study.
  15. Has received any compound within 60 days of enrollment.
  16. Has received any biologics within 60 days of enrollment.
  17. Has received any within 30 days prior to enrollment.
  18. Has conditions which, in the opinion of the investigator, may interfere with the participant's ability to comply with the study procedures.
  19. Has any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal (GI), genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.
  20. Has a history of or allergies to vedolizumab or its components.
  21. Has had prior exposure to vedolizumab, natalizumab, efalizumab, or rituximab.
  22. Had a surgical procedure requiring general anesthesia within 30 days prior to screening or is planning to undergo major surgery during the study period.
  23. Has a history of , except for the following: adequately-treated nonmetastatic basal cell skin cancer; squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to Screening; and history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to screening. Participants with a remote history of malignancy (eg, >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to enrollment.
  24. Has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  25. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist during Screening or prior to the administration of study drug.
  26. Has any of the following laboratory abnormalities during the Screening Period:

    i. level \<8 g/dL. ii. White blood cell (WBC) count \<3*10\^9/L. iii. Lymphocyte count \<0.5*10\^9/L. iv. count \<100*10\^9/L or >1200*10\^9/L. v. (ALT) or aspartate aminotransferase (AST) >3*the (ULN).

    vi. Alkaline phosphatase >3*ULN. vii. Serum creatinine >2*ULN.

  27. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to enrollment.
  28. Has an active psychiatric problem that, in the investigator's opinion, may interfere with compliance with study procedures.
  29. Is unable to attend all the study visits or comply with study procedures.
  30. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 18 weeks after participating in this study; or intending to donate ova during such time period.
  31. If male, the participant intends to donate sperm during the course of this study or for 18 weeks thereafter.
  32. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  33. Participants who are at sites participating in the magnetic resonance enterography (MREn) substudy may not participate if they have intolerance or contraindication to the procedure or if any of the following exclusions apply:

    1. Has certain implanted medical devices, such as pacemakers or implantable cardioverter defibrillators (ICDs), or ferromagnetic metallic foreign bodies, such as shrapnel or certain tattoos.
    2. Has allergy to gadolinium-based magnetic resonance (MR) IV contrast agents.
    3. Has known claustrophobia.
    4. Has estimated (eGFR) \<30 mL/min/1.73 m\^2 at Screening.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Vedolizumab 300 mg

    Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.

    Drug: Vedolizumab

Interventions

  • Vedolizumab intravenous injection

    Also known as: MLN0002

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of Participants Achieving Endoscopic Remission at Week 26

    Endoscopic remission is defined as a simple endoscopic score for Crohn's Disease (SES-CD) score of ≤4. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Week 26

Secondary outcomes

  1. Part A: Percentage of Participants Achieving Complete Mucosal Healing at Week 26

    Complete mucosal healing is defined as absence of ulceration.

    Time frame: Week 26

  2. Part B: Percentage of Participants Achieving Complete Mucosal Healing at Week 52

    Complete mucosal healing is defined as absence of ulceration.

    Time frame: Week 52

  3. Part A: Percentage of Participants Achieving Endoscopic Remission at Week 14

    Endoscopic remission is defined as a SES-CD score of ≤4. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Week 14

  4. Part B: Percentage of Participants Achieving Endoscopic Remission at Week 52

    Endoscopic remission is defined as a SES-CD score of ≤4. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Week 52

  5. Part A: Percentage of Participants With Endoscopic Response at Week 14

    Endoscopic response is defined as a reduction in SES-CD from Baseline by ≥50%. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Baseline and Week 14

  6. Part A: Percentage of Participants With Endoscopic Response at Week 26

    Endoscopic response is defined as a reduction in SES-CD from Baseline by ≥50%. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Baseline and Week 26

  7. Part B: Percentage of Participants With Endoscopic Response at Week 52

    Endoscopic response is defined as a reduction in SES-CD from Baseline by ≥50%. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Baseline and Week 52

  8. Part A: Percentage of Participants Achieving Clinical Response at Week 10

    Clinical response is defined as Crohn's Disease Activity Index (CDAI) decrease from Baseline of ≥100 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

    Time frame: Baseline and Week 10

  9. Part A: Percentage of Participants Achieving Clinical Response at Week 26

    Clinical response is defined as CDAI decrease from Baseline of ≥100 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

    Time frame: Baseline and Week 26

  10. Part B: Percentage of Participants Achieving Clinical Response at Week 52

    Clinical response is defined as CDAI decrease from Baseline of ≥100 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

    Time frame: Baseline and Week 52

  11. Part A: Percentage of Participants Achieving Clinical Remission at Week 10

    Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

    Time frame: Week 10

  12. Part A: Percentage of Participants Achieving Clinical Remission at Week 26

    Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

    Time frame: Week 26

  13. Part B: Percentage of Participants Achieving Clinical Remission at Week 52

    Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

    Time frame: Week 52

  14. Part B: Percentage of Participants With Durable Clinical Remission

    Durable clinical remission is defined as clinical remission at both Week 26 and Week 52. Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The percentage of participants assessed at Week 52 who had clinical remission at Week 26 of Part A and also had clinical remission at Week 52 is reported.

    Time frame: Weeks 26 and 52

07

Results

Posted Sep 14, 2018

Participant flow

Participants took part in the study at 42 investigative sites in Belgium, Canada, Czech Republic, France, Hungary, Italy, Poland and the United States from 30 March 2015 to 21 February 2018.

Part A: Treatment Period
Participant flow — Part A: Treatment Period
MilestoneVedolizumab 300 mg
Started101
Completed78
Not completed23
Withdrew: Pretreatment event/adverse event2
Withdrew: Lack of efficacy15
Withdrew: Voluntary withdrawal4
Withdrew: Lost to follow-up2
Part B: Treatment Extension Period
Participant flow — Part B: Treatment Extension Period
MilestoneVedolizumab 300 mg
Started56
Completed46
Not completed10
Withdrew: Pretreatment event/adverse event(s)3
Withdrew: Lack of efficacy7

Outcome measures

PrimaryPart A: Percentage of Participants Achieving Endoscopic Remission at Week 26

Endoscopic remission is defined as a simple endoscopic score for Crohn's Disease (SES-CD) score of ≤4. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Achieving Endoscopic Remission at Week 26
percentage of participantsVedolizumab 300 mg
Part A: Percentage of Participants Achieving Endoscopic Remission at Week 2611.9 (6.3 to 19.8)
SecondaryPart A: Percentage of Participants Achieving Complete Mucosal Healing at Week 26

Complete mucosal healing is defined as absence of ulceration.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Achieving Complete Mucosal Healing at Week 26
percentage of participantsVedolizumab 300 mg
Part A: Percentage of Participants Achieving Complete Mucosal Healing at Week 2614.9 (8.6 to 23.3)
SecondaryPart B: Percentage of Participants Achieving Complete Mucosal Healing at Week 52

Complete mucosal healing is defined as absence of ulceration.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Achieving Complete Mucosal Healing at Week 52
percentage of participantsVedolizumab 300 mg
Part B: Percentage of Participants Achieving Complete Mucosal Healing at Week 5217.9 (8.9 to 30.4)
SecondaryPart A: Percentage of Participants Achieving Endoscopic Remission at Week 14

Endoscopic remission is defined as a SES-CD score of ≤4. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Achieving Endoscopic Remission at Week 14
percentage of participantsVedolizumab 300 mg
Part A: Percentage of Participants Achieving Endoscopic Remission at Week 1416.8 (10.1 to 25.6)
SecondaryPart B: Percentage of Participants Achieving Endoscopic Remission at Week 52

Endoscopic remission is defined as a SES-CD score of ≤4. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Achieving Endoscopic Remission at Week 52
percentage of participantsVedolizumab 300 mg
Part B: Percentage of Participants Achieving Endoscopic Remission at Week 5216.1 (7.6 to 28.3)
SecondaryPart A: Percentage of Participants With Endoscopic Response at Week 14

Endoscopic response is defined as a reduction in SES-CD from Baseline by ≥50%. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Baseline and Week 14
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Endoscopic Response at Week 14
percentage of participantsVedolizumab 300 mg
Part A: Percentage of Participants With Endoscopic Response at Week 1433.7 (24.6 to 43.8)
SecondaryPart A: Percentage of Participants With Endoscopic Response at Week 26

Endoscopic response is defined as a reduction in SES-CD from Baseline by ≥50%. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Endoscopic Response at Week 26
percentage of participantsVedolizumab 300 mg
Part A: Percentage of Participants With Endoscopic Response at Week 2624.8 (16.7 to 34.3)
SecondaryPart B: Percentage of Participants With Endoscopic Response at Week 52

Endoscopic response is defined as a reduction in SES-CD from Baseline by ≥50%. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is the sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Endoscopic Response at Week 52
percentage of participantsVedolizumab 300 mg
Part B: Percentage of Participants With Endoscopic Response at Week 5251.8 (38.0 to 65.3)
SecondaryPart A: Percentage of Participants Achieving Clinical Response at Week 10

Clinical response is defined as Crohn's Disease Activity Index (CDAI) decrease from Baseline of ≥100 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

Time frame:
Baseline and Week 10
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Achieving Clinical Response at Week 10
percentage of participantsVedolizumab 300 mg
Part A: Percentage of Participants Achieving Clinical Response at Week 1054.5 (44.2 to 64.4)
SecondaryPart A: Percentage of Participants Achieving Clinical Response at Week 26

Clinical response is defined as CDAI decrease from Baseline of ≥100 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Achieving Clinical Response at Week 26
percentage of participantsVedolizumab 300 mg
Part A: Percentage of Participants Achieving Clinical Response at Week 2660.4 (50.2 to 70.0)
SecondaryPart B: Percentage of Participants Achieving Clinical Response at Week 52

Clinical response is defined as CDAI decrease from Baseline of ≥100 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Achieving Clinical Response at Week 52
percentage of participantsVedolizumab 300 mg
Part B: Percentage of Participants Achieving Clinical Response at Week 5258.9 (45.0 to 71.9)
SecondaryPart A: Percentage of Participants Achieving Clinical Remission at Week 10

Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Achieving Clinical Remission at Week 10
percentage of participantsVedolizumab 300 mg
Part A: Percentage of Participants Achieving Clinical Remission at Week 1035.6 (26.4 to 45.8)
SecondaryPart A: Percentage of Participants Achieving Clinical Remission at Week 26

Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Part A: Percentage of Participants Achieving Clinical Remission at Week 26
percentage of participantsVedolizumab 300 mg
Part A: Percentage of Participants Achieving Clinical Remission at Week 2641.6 (31.9 to 51.8)
SecondaryPart B: Percentage of Participants Achieving Clinical Remission at Week 52

Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Achieving Clinical Remission at Week 52
percentage of participantsVedolizumab 300 mg
Part B: Percentage of Participants Achieving Clinical Remission at Week 5250.0 (36.3 to 63.7)
SecondaryPart B: Percentage of Participants With Durable Clinical Remission

Durable clinical remission is defined as clinical remission at both Week 26 and Week 52. Clinical remission is defined as CDAI score of ≤150 points. CDAI is a scoring system for the assessment of Crohn's Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The percentage of participants assessed at Week 52 who had clinical remission at Week 26 of Part A and also had clinical remission at Week 52 is reported.

Time frame:
Weeks 26 and 52
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Durable Clinical Remission
percentage of participantsVedolizumab 300 mg
Part B: Percentage of Participants With Durable Clinical Remission37.5 (24.9 to 51.5)

Adverse events

Collected over First dose of study drug and up to the last dose or early termination plus 18-week follow-up if applicable (Up to 44 Weeks for Part A Treatment and Up to 70 Weeks for Part B Extension). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vedolizumab 300 mg Part A0/101 (0%)12/101 (11.9%)26/101 (25.7%)
Vedolizumab 300 mg Part B0/56 (0%)6/56 (10.7%)9/56 (16.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventVedolizumab 300 mg Part AVedolizumab 300 mg Part B
Crohn's diseaseGastrointestinal disorders6/1011/56
Coronary artery diseaseCardiac disorders0/1011/56
SubileusGastrointestinal disorders0/1011/56
Infected biteInfections and infestations0/1011/56
Urinary tract infectionInfections and infestations0/1011/56
Postoperative ileusInjury, poisoning and procedural complications0/1011/56
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1011/56
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1011/56
Anal fistulaGastrointestinal disorders1/1010/56
AstheniaGeneral disorders1/1010/56
Most frequent other events
Most frequent other events
EventVedolizumab 300 mg Part AVedolizumab 300 mg Part B
Crohn's diseaseGastrointestinal disorders12/1015/56
Viral upper respiratory tract infectionInfections and infestations6/1013/56
Abdominal painGastrointestinal disorders5/1013/56
HeadacheNervous system disorders5/1010/56
NauseaGastrointestinal disorders5/1010/56

Baseline characteristics

Full Analysis Set (FAS) included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Vedolizumab 300 mg
Mean38.0 ± 14.00
Sex: Female, Male
Sex: Female, Male(Participants)Vedolizumab 300 mg
Female49
Male52
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vedolizumab 300 mg
Hispanic or Latino1
Non-Hispanic and Latino32
Not Collected68
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vedolizumab 300 mg
Asian2
Black or African American1
White98
Region of Enrollment
Region of Enrollment(Participants)Vedolizumab 300 mg
Belgium8
Canada14
Czech Republic14
France2
Hungary14
Italy9
Poland7
United States33
Height
Height(cm)Vedolizumab 300 mg
Mean172.5 ± 9.81
Weight
Weight(kg)Vedolizumab 300 mg
Mean73.94 ± 18.795
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vedolizumab 300 mg
Mean24.71 ± 5.365

3 further baseline measures are reported on the registry.

08

Study locations

81 sites
  • La Jolla, California, United States
  • Hamden, Connecticut, United States
  • Gainesville, Florida, United States
  • Inverness, Florida, United States
  • Maitland, Florida, United States
  • Miami, Florida, United States
  • Winter Park, Florida, United States
  • Macon, Georgia, United States
  • Suwanee, Georgia, United States
  • Topeka, Kansas, United States
  • Baton Rouge, Louisiana, United States
  • Columbia, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Saint Louis, Missouri, United States
  • Manhasset, New York, United States
  • Poughkeepsie, New York, United States
  • Winston-Salem, North Carolina, United States
  • Cleveland, Ohio, United States
  • Tulsa, Oklahoma, United States
  • Portland, Oregon, United States
  • Germantown, Tennessee, United States
  • Bonheiden, Belgium
  • Bruxelles, Belgium
  • Herentals, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Roeselare, Belgium
  • Vancouver, British Columbia, Canada
  • Victoria, British Columbia, Canada
  • Halifax, Nova Scotia, Canada
  • London, Ontario, Canada
  • Vaughan, Ontario, Canada
  • Hradec Kralove, Czechia
  • Kladno, Czechia
  • Pardubice, Czechia
  • Praha 10, Czechia
  • Praha 4, Czechia
  • Praha 7, Czechia
  • Nice Cedex 3, Alpes Maritimes, France
  • Pessac, Gironde, France
  • Saint Etienne, Loire, France
  • Reims, Marne, France
  • Lille cedex, Nord, France
  • Lille Cedex, France
  • Nantes Cedex 1, France
  • Nice Cedex 3, France
  • Pessac, France
  • Reims, France
  • Saint Etienne, France
  • Toulouse Cedex 09, France
  • Bekescsaba, Hungary
  • Budapest, Hungary
  • Debrecen, Hungary
  • Gyongyos, Hungary
  • Gyula, Hungary
  • Jaszbereny, Hungary
  • Kistarcsa, Hungary
  • Miskolc, Hungary
  • Mosonmagyarovar, Hungary
  • Pecs, Hungary
  • Szeged, Hungary
  • Szekesfehervar, Hungary
  • Szekszard, Hungary
  • Vac, Hungary
  • San Giovanni Rotondo, Foggia, Italy
  • Rozzano, Milano, Italy
  • San Donato Milanese, Milano, Italy
  • Bologna, Italy
  • Firenze, Italy
  • Napoli, Italy
  • Padova, Italy
  • Roma, Italy
  • Rozzano, Italy
  • San Donato Milanese, Italy
  • San Giovanni Rotondo, Italy
  • Bialystok, Poland
  • Elblag, Poland
  • Poznan, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
09

References and documents

Publications

  • Narula N, Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. Am J Gastroenterol. 2022 Jul 1;117(7):1106-1117. doi: 10.14309/ajg.0000000000001795. Epub 2022 Apr 15. PubMed 35435862 ↗
  • Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology. 2019 Oct;157(4):1007-1018.e7. doi: 10.1053/j.gastro.2019.06.038. Epub 2019 Jul 4. PubMed 31279871 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Jun 2017, 26 months.

Results were first posted in Sep 2018, 1 year 3 months after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 26 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2015
First posted
Apr 23, 2015
StartActual
Mar 30, 2015
Primary completionActual
Jun 2, 2017
CompletionActual
Feb 21, 2018
Results first posted
Sep 14, 2018
Last update
Sep 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02425111
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 23, 2015
Start date
Mar 30, 2015
Primary completion
Jun 2, 2017
Completion
Feb 21, 2018
Results posted
Sep 14, 2018
Last update
Sep 14, 2018

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion